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Abstract FGFR2 is recurrently amplified in 5% of gastric cancers and 1%–4% of breast
cancers; however, this molecular alteration has never been reported in a primary
colorectal cancer specimen. Preclinical studies indicate that several FGFR tyrosine-kinase
inhibitors (TKIs), such as AZD4547, have in vitro activity against the FGFR2-amplified
colorectal cell line, NCI-H716. The efficacy of these inhibitors is currently under
investigation in clinical trials for breast and gastric cancer. Thus, better characterizing
colorectal tumors for FGFR2 amplification could identify a subset of patients who may
benefit from FGFR TKI therapies. Here, we describe a novel FGFR2 amplification
identified by clinical next-generation sequencing in a primary colorectal cancer. Further
characterization of the tumor by immunohistochemistry showed neuroendocrine
differentiation, similar to the reported properties of the NCI-H716 cell line. These
findings demonstrate that the spectrum of potentially clinically actionable mutations
detected by targeted clinical sequencing panels is not limited to only single-nucleotide
polymorphisms and insertions/deletions but also to copy-number alterations.
[Supplemental material is available for this article.]
INTRODUCTION
Colorectal cancer (CRC) is a leading cause of mortality and morbidity and constitutes the
third most common malignancy diagnosed in both men and women (Siegel et al. 2016).
CRC tumors are generally divided into two broad, but biologically distinct, molecular sub-
types: tumors characterized by microsatellite instability (MSI) and tumors characterized by
chromosomal instability (CI). MSI occurs when mismatch repair (MMR) pathways become in-
activated, either through methylation of the MLH1 promoter (typically in a CpG island meth-
ylator phenotype background) or through mutational inactivation of MLH1 and/or other
MMR pathway genes. MSI tumors constitute ∼15% of sporadic CRC cases. They typically
present in the right hemicolon and are associated with BRAF V600E mutations (Cancer
Genome Atlas2012). CI tumorsconstitute∼85%of sporadic CRC cases. Thisheterogeneous
group is characterized by mutations in APC, KRAS, and TP53, as well as frequent, recurrent
somatic copy-number alterations (SCNAs) (Cancer Genome Atlas 2012; Wang et al. 2015).
Although many recurrent mutations have been identified in CRC, only a few have been
validated as predictive biomarkers. Anti-EGFR antibody therapy (e.g., panitumumab and
cetuximab) has proven effective in metastatic tumors with wild-type MAPK pathway genes
(Amado et al. 2008), but mutations in tumors with KRAS, NRAS, and/or BRAF confer
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decreased sensitivity to these drugs (National Comprehensive Cancer Network 2016).
Likewise, the clinical importance of most of the reported SCNAs is uncertain (Wang et al.
2015), but rarely a clinically actionable discovery is made. In a case report of a patient with
CRC with amplification and overexpression of ERBB2, a dramatic radiographic response
was observed upon treatment with trastuzumab (Sorscher 2011), similar to the response ob-
served in ERBB2-amplified metastatic breast cancer (Vogel et al. 2002).
Here, we present the multiplatform, pathologic characterization of a case of CRC submit-
ted for routine clinical analysis. This sample was subjected to next-generation sequencing
(NGS) following hybrid capture–based enrichment of a 425-kb target space. Although this
assay was intended to detect single-nucleotide variants and small insertions and deletions
(indels) in cancer relevant genes, a read depth (>5000×, reference mean 1135×) suggestive
of a focal amplification was noted at the FGFR2 locus, a SCNA that is considered medically
actionable in other cancer types. Bioinformatic software designed to predict SCNA from tu-
mor samples confirmed the FGFR2 amplification from sequencing data, and findings were
verified by chromosomal microarray and fluorescence in situ hybridization (FISH). This is
the first report of a FGFR2 amplification in a non-cell-line-derived, clinical CRC specimen ob-
tained during the course of routine pathologic examination. Thiscase highlights the utility of
SCNA prediction from clinical NGS data, as copy-number variations can be detected in the
absence of predefined expectations.
RESULTS
Clinical Presentat ion
A 56-yr-old female with a questionable history of ulcerative colitis underwent a total abdom-
inal colectomy for a 6-cm, poorly differentiated, signet-ring adenocarcinoma in the sigmoid
colon (Fig. 1, top inset). The specimen revealed transmural and serosal involvement of the
perirectal and pericolic soft tissue by the tumor, aswell aswidespread lymphovascular space
invasion and metastatic involvement of 14 of 18 pericolonic lymph nodes. Altogether, this
constituted stage IIIC disease. MMR markers MLH1, PMS2, MSH2, and MSH6 showed re-
tained expression by immunohistochemistry (IHC) (Fig. 2).
Adjuvant chemotherapy with a standard first-line regimen (FOLFOX) was initiated but
stopped after eight cycles because of side effects. Further imaging was performed to assess
the disease status. This revealed bulky retroperitoneal and portahepatic lymphadenopathy,
multiple metastatic, cardiophrenic lymph nodes, and multiple hepatic lesions. A fine needle
aspiration of a liver lesion confirmed metastasis, indicating stage IV disease; however, there
was insufficient tissue for further molecular studies. An alternative regimen (FOLFIRI) was
then initiated, and tissue from the patient’s primary colon cancer resection specimen was
submitted to Genomics and Pathology Services at Washington University in Saint Louis
(GPS@WUSTL) for mutational profiling. The GPS panel (described below) is a next-genera-
tion sequencing–based panel that targets 48 common cancer genes and is performed in a
certified clinical environment, permitting return of patient results and third-party billing.
Genomic Analysis, Microarray, and FISH
A single reportable mutation, TP53 p.D281E (Chr17:g.7577095G>T; NM_000546:
c.843C>A), was identified among the 48 genes analyzed on the GPS@WUSTL solid
tumor panel (Table 1). According to the COSMIC (Forbes et al. 2015) and IARC TP53
mutation (Petitjean et al. 2007) databases, the p.D281E variant in TP53 has been described
as a deleterious somatic mutation in various carcinomas, although it has not been specif-
ically previously reported in CRC. Functional data from promoter response element
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transactivation experiments indicate that this variant results in loss of protein function
(Jordan et al. 2010).
Standard quality control metrics indicated significant depth of coverage in the region of
the FGFR2 gene. To further explore the possibility of copy-number variation (CNV), genome-
wide copy-number information wasextracted from the targeted NGSdata using two somatic
copy-number aberration detection tools: CopywriteR (Kuilman et al. 2015) and CNVkit
(Talevich et al. 2014, 2016). Both tools revealed a focal copy number amplification involving
the FGFR2 locus in a background of chromosomal aneuploidy (Fig. 3A,B). Consistent with
NGSread depths, microarray data confirmed the presence of a focal, somatic FGFR2 ampli-
fication (Fig. 3B). The 1.08-Mb amplified region encompassed the entirety of the FGFR2
gene, along with the 3′ genic regions of WDR11 and ATE1 (hg19 Chr 10:122,608,791-
123,684,530). FISH also revealed a striking amplification of FGFR2 in tumor-involved tissue
(Fig. 3C). Among 100 analyzed nuclei in the tumor tissue, the average RP11-62L18 probe sig-
nal corresponding to FGFR2 was 63.91, whereas the average chromosome enumeration
probe (CEP) 10 control signal was 2.64, yielding a ratio of 24.2. Analysis of the patient’s nor-
mal colonic tissue demonstrated an average RP11-62L18 (FGFR2)signal number of 1.92 and
Figure 1. Neuroendocrine marker immunostains. (Top) H&E, 2×. Poorly differentiated, signet-ring adenocar-
cinoma showing abundant mucin in thissection. (Bottom left)Synaptophysin, 20×. Focal expression present in
the malignant cells. (Bottom right) Chromogranin, 20×. Malignant glands showing patchy expression.
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average CEP10 signal number of 1.87, yielding a ratio of 1.02. FGFR2 gene amplification has
only recently been documented in CRC, where it was identified in the NCI-H716 colon can-
cer cell line (Mathur et al. 2014).
Protein Expression Analysis with IHC
The NCI-H716 CRC cell line harboring the FGFR2 amplification hasfeaturesof endocrine dif-
ferentiation, which is unusual for CRC. IHC studies indicated that NCI-H716 shows expres-
sion of chromogranin A, mucin, glucagon-like peptide-1 (GLP-1), and receptors for
gastrin, somatostatin, and serotonin (de Bruïne et al. 1992; Reimer et al. 2001). We followed
up on this observation, assessing the extent of neuroendocrine differentiation in the pa-
tient’s tumor by assessing the expression of synaptophysin and chromogranin A using IHC
assays commonly implemented in the anatomic pathology laboratory. Patchy expression
of chromogranin and focal expression of synaptophysin was noted in the malignant cells
of the tumor specimen, comprising ∼10%and <5%of the total tumor cellularity, respectively
(Fig. 1).
Figure 2. MMR immunostains showing retained expression of all four MMR markers. (Top left) MLH1, 20×.
(Top right) MSH2, 20×. (Bottom left) MSH6, 20×. (Bottom right) PMS2, 20×.
Table 1. Detected somatic variants
Chr Location Class Gene
Allele
change RefSeq ID cDNA pos AA change Mutation dbSNP
SIFT
score
PolyPhen-
2 pred
Mutation
type
Cancer
gene
No. of
reads
ref/alt Genotype
Chr17 7577095 SNV TP53 G>T NM_000546 NM_000546:
c.843C>A
NP_000537:
p.D281E
missense N/A 0.01 0.973 somatic Y 423/
405
Het
AA, amino acid; dbSNP, Database for Short Genetic Variations; SIFT, Sorting Intolerant from Tolerant; PolyPhen-2, Polymorphism Phenotyping v2; SNV, single-
nucleotide variant.
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DISCUSSION
NGS-based profiling of the tumor genome identified a single nonsynonymous mutation
among the many genes noted for recurrent mutations in CRC (e.g., KRAS, NRAS, BRAF,
PIK3CA)and a striking focal amplification of the FGFR2 gene. FGFR2 amplification isthought
to occur in 5% of gastric cancersand 1%–4% of breast cancers (Heiskanen et al. 2001; Turner
et al. 2010; Jung et al. 2012). In gastric cancer, FGFR2 amplification isassociated with poorer
overall survival (Su et al. 2014; Shoji et al. 2015). Preclinical, in vitro, and in vivo studies
Figure 3. Multimodal analysis of FGFR2 in the tumor. (A) Targeted NGS-based virtual karyotype (CNVkit)
showing background aneuploidy and an amplification event involving a focal region of Chromosome 10
(Chr10:122737302–123454446) that includesFGFR2. (B)Cytoscan microarray output from the tumor tissue re-
vealing amplification of the region involving FGFR2. (C) Fluorescence in situ hybridization of tumor-involved
(Tumor) and tumor-uninvolved (Control) colonic tissue from the patient’s colectomy. FGFR2 probe (RP11–
62L18, red) to Chromosome 10 enumeration probe (CEP 10, green) ratio showing a high copy-number ratio
of 24.2 in the tumor (right) versus 1.92 in the control (left).
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suggest that breast and gastric cancer cell lines with FGFR2 amplifications may be sensitive
to FGFR inhibitors (Jain and Turner 2012; Xie et al. 2013); clinical trials are ongoing.
The only report of FGFR2 amplification in CRC was from the NCI-H716 colon cancer cell
line (Mathur et al. 2014). Through a series of functional assays, Mathur et al.’s (2014) study
demonstrated that NCI-H716 cells are dependent on FGFR2 amplification and overexpres-
sion for survival and proliferation, and they appear to be sensitive to FGFRinhibitors (Mathur
et al. 2014; Medico et al. 2015). To ascertain the frequency of this molecular event and the
resultant FGFR2 protein overexpression, Mathur et al. performed FGFR2 IHC on a series of
primary and lymph node–metastatic CRC samplesin a tissue microarray. Although they iden-
tified FGFR2 overexpression of five samples (1.5% of >300 tested from various body sites),
FISH was negative for FGFR2 amplification in all samples tested. Thus, this is the first report
to identify FGFR2 amplification in a CRC tumor sample obtained directly from a patient’spri-
mary tumor and the first non-cell-line-derived, clinical case harboring the aberration.
Although not reported as part of the clinical panel, analysis of the raw sequencing data
by CopywriteR and CNVkit also demonstrated an amplification of the ASXL1 gene
(Supplemental Table 1); the ASXL1 gene and 51 other genes were targeted by the clinical
sequencing panel but were not analyzed or reported asthe part of the solid tumor gene pan-
el. The ASXL1 gene is involved in chromatin modification and is mutated in up to 20% of
myelodsyplastic syndrome cases and a smaller percentage of acute myeloid leukemias
(Cancer Genome AtlasResearch et al. 2013; Haferlach et al. 2014). In hematologic malignan-
cies ASXL1 mutations tend to be small insertions or deletions that result in frameshifts.
However, ASXL1 amplifications appear to be reasonably common in solid tumors and are
present in >20% of uterine carcinosarcomas and ∼10% of colorectal cancers, according to
TCGA data (Cancer Genome Atlas 2012; Zhao et al. 2016). ASXL1 amplifications have no
known prognostic significance in solid tumors and may be part of larger genomic events
that span several genes on Chromosome 20.
The NCI-H716 cell line hasbeen demonstrated to expresschromogranin A, mucin, GLP-1,
and receptors for gastrin, somatostatin, and serotonin (de Bruïne et al. 1992; Reimer et al.
2001). We followed up on thispotential insight byassessing the extent of neuroendocrine dif-
ferentiation of our case by utilizing the standard, routine IHC stainscommonly used in the an-
atomic pathology laboratory for thispurpose: synaptophysin and chromogranin A. We found
the patient’s tumor had focal to patchy staining of both markers, indicating some partial neu-
roendocrine differentiation, similar to the NCI-H716 cell line. However, it has been docu-
mented that up to 40% of CRCs may have detectable neuroendocrine marker expression
by IHC (Bosman and World Health Organization 2010). Furthermore, according to the
World Health Organization classification scheme for digestive tumors, a CRC specimen
must show 30% of an adenocarcinoma and a neuroendocrine component, each, to qualify
for classification as a “ mixed adenoneuroendocrine carcinomas (MANEC)” (International
Classification of Diseases, ICD10: C18–C20) (Bosman and World Health Organization
2010). Our case fell short of these criteria. Nevertheless, this association possibly suggests
an interesting association that may warrant further inquiry. The spectrum of molecular abnor-
malities present in MANECs is a poorly studied area, with only case reports and small case
series in the literature that primarily survey small genomic changes, such assingle-nucleotide
variants and indels of <10 bp (Scardoni et al. 2014; Vanacker et al. 2014). In one study that
examined six cases of MANEC by targeted NGS panel, TP53 mutations were the most fre-
quently identified molecular abnormality (Scardoni et al. 2014). To the best of our knowledge,
no study hascomprehensively surveyed the SCNAspresent in MANECsor CRCswith neuro-
endocrine differentiation, precluding the comparison of our case to the frequency of FGFR2
amplification in neuroendocrine-expressing CRC based on the known, extant literature.
The striking signet-ring morphology of the tumor cells in this case, the lack of an identi-
fiable adenomatous mucosal component, and the neuroendocrine differentiation are also
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very reminiscent of goblet cell carcinoids (GCCs) (International Classification of Diseases,
ICD10: C23–C24). However, GCCs are anatomically located within the vermiform appendix,
almost exclusively (Roy and Chetty 2010). Similar to the scenario with MANECs, no compre-
hensive SCNA study exists in the literature for GCCs, likely as a consequence of their rarity.
Interestingly, the NCI-H716 index case is derived from the cecum, which is anatomically
proximal to the appendix. Although NCI-H716 was formally diagnosed as a colorectal ade-
nocarcinoma, and GCC had been described at least a decade prior to the development of
the NCI-H716 cell line, GCC was not a widely recognized diagnostic entity at the time (Park
et al. 1987; Pahlavan and Kanthan 2005; Gagnon and Brubaker 2016). Similar to the scenario
with MANECs, no comprehensive SCNA study exists in the literature for GCCs. However,
loss of heterozygosity was frequently identified in the 16 cases of GCCs included in a study
that used targeted dinucleotide microsatellite markers for 11q, 16q, and 18q, a pattern as-
sociated with midgut carcinoids (Stancu et al. 2003). Chromosome 11 is present in a single
copy in the NCI-H716 cell line, but Chromosomes 16 and 18 are present at normal levels
(Atcc 2016). None of these cytogenomic abnormalities were identified in our case.
Finally, this case report demonstrates that potentially actionable copy-number alter-
ations can be detected from NGSdata generated from small, targeted, clinical NGSpanels.
Although only a minority of clinical laboratoriescurrently report SCNAsaspart validated clin-
ical testing, evidence of large amplifications, such as this FGFR2 amplification, can be sug-
gested by a review of the coverage-based QC metrics at case sign-out. In the absence of a
formally validated SCNA detection pipeline, clinical laboratories may opt to detect copy
gains by simply imposing an upper boundary for gene level coverage (e.g., 5000×, given
a mean reference coverage depth of 1132×). Going forward it hasbecome increasingly clear
that SCNA detection will become an important part of clinical molecular genetic testing.
In conclusion, the genomic, histologic, and IHC characterization of a clinical case of pri-
mary CRC with FGFR2 amplification unveiled phenotypic and genotypic similarities with the
index cell line case for the CRC cell line NCI-H716. Currently, it remainsunclear how frequent
FGFR2 amplificationsare in patientswith CRC, much less in CRC with neuroendocrine differ-
entiation or GCC morphology. The insight contributed by this report will be helpful in iden-
tifying the CRC patient cohort that can potentially benefit from FGFR tyrosine-kinase
inhibitor therapy and in further establishing and clarifying the possible association between
neuroendocrine differentiation, mucinous signet-ring morphology, and FGFR2 amplifica-
tion. Moreover, these findings demonstrate the utility of routine, clinical NGS panels in un-
covering novel, potentially actionable, somatic mutations in cancer.
METHODS
Next-Generat ion Sequencing and Data Analysis
Genomic DNA was isolated from a formalin-fixed paraffin-embedded (FFPE) tissue block
originating from the primary colon resection specimen using the QIAamp DNeasy Blood
and Tissue Kit (QIAGEN), and sample quality and quantity was assessed by Qubit
(Thermo Fisher Scientific) and Nanodrop (Thermo Fisher Scientific). Seven hundred and fifty
nanogramsof DNA wassheared in the Covaris S220 series sonicator to an average fragment
size of 140–230 bp, as measured by Bioanalyzer (Agilent Technologies). Fragmented DNA
was end-repaired, A-tailed, and indexed using the KAPA Hyper Prep Kit (KAPA
Biosystems). Adapter-ligated DNA was subjected to limited amplification prior to hybridiza-
tion with custom cDNA capture probes (IDT). The total size of the target space was 425 kb,
encompassing all coding exonsof 99 cancer relevant genes, selected introns, and intergenic
regions targeted for quality control. The hybridized product was washed, amplified with the
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KAPA amplification kit, and sequenced on an Illumina HiSeq 2500 to generate 2× 101-bp
paired-end reads.
Analysis and interpretation was performed as previously described (Hagemann et al.
2014).
Reads were aligned to the human reference (UCSC build hg19 / NCBI build 37.2) using
Novoalign (Novocraft Technologies). PCRduplicateswere marked with Picard Tools (version
1.53, http://picard.sourceforge.net), and alignment files were converted to mpileup format
using SAMtools (version 0.1.18-0.1.19; Li et al. 2009). Single-nucleotide variants (SNVs)
with depth ≥50× and Fisher’s exact test of strand bias ≤100 were detected using
VarScan2 (version 2.3.6; Koboldt et al. 2009), and visualized in Integrative Genomics
Viewer (version 2.0.16 or later; Robinson et al. 2011). Reports were generated using the
Clinical Genomicist Workstation v2.1.1 (PierianDx). Single-nucleotide variants with global
mean allele frequencies in the population of >1% were considered “ known SNPs” and ex-
cluded from this report. Nonsynonymous SNVs that were not known polymorphisms were
deemed clinically relevant and reportable. Quality and gene-level read depth metrics are
available in Supplemental Tables S1 and S2.
Copy-Number Analysis
Copy-number profiles were determined by CopywriteR (Kuilman et al. 2015) and CNVkit
(Talevich et al. 2014, 2016) using the same alignment files employed in SNV calling.
CopywriteR was run with window size set to 50 kb and no matched or normal reference.
CNVkit’s standard batch pipeline was run with default parameters. Fifteen FFPE tissue sam-
ples from patients without cancer and previously processed through the same analysis pipe-
line were included as pooled controls to facilitate the required normalization for CNVkit; to
further confirm the absence of CNAs in these 15 control samples, all cases were tested by
CopywriteR (which does not require normal controls) and showed no evidence of CNAs.
Microarray
Copy-number alteration was assessed using the Affymetrix CytoScan HD array (Affymetrix)
containing approximately 2.67 million markers including 1.9 million nonpolymorphic probes
and nearly 750,000 probes capable of single-nucleotide polymorphism (SNP) detection.
DNA wasderived from two sectionsof the patient’scolectomy specimen representing tumor
and normal colonic mucosa. Beginning with 1 μg of input DNA, the specimens were enzy-
matically digested, adaptor-ligated, and amplified prior to hybridization on the array
platform. Data were derived using an Affymetrix GeneChip Scanner 3000 7G and copy-
number status was determined in comparison to an in silico FFPE-specific reference file
(CytoScanHD_Array.na33.r2.FFPE.v3.REF_MODEL). Analysiswasperformed using Chromo-
some Analysis Suite v3.1.0.15 (Affymetrix).
Fluorescence In Situ Hybridizat ion
FISH was performed using the BAC clone, RP11-62L18 (Empire Genomics), mapping to the
FGFR2 gene and with CEP 10 (Empire Genomics) mapping to the centromeric region of
Chromosome 10. FFPE tumor-involved and normal colonic tissue from the patient were sec-
tioned at 5 microns and mounted on positively charged slides. Corresponding hematoxylin
and eosin (H&E)-stained slideswere reviewed by a pathologist to mark for areasof tumor and
normal tissue and then transcribed to the unstained slides for FISH. Slides were deparaf-
finized with Citra Solv and dehydrated in 100% ethanol before specimen pretreatment using
the Pretreatment kit II (Abbott Molecular) including Pretreatment solution (NaSCN) at 80°C,
Protease (Pepsin 2500–3000 U/mg, lyophilized) in Protease buffer (0.2 N HCI) at 37°C. After
an ethanol dehydration series (70%, 85%, and 100%), slides were air-dried, and 12 µL of
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probe mixture wasapplied. Coverslipped, sealed slideswere then placed in a preheated 73°
C slide moat (Boekel Scientific), allowing the patient DNA and the probe to denature for 5
min, followed by an overnight hybridization at 37°C. Posthybridization wash was performed
using 2× SSC at 74 ± 1°C and 2× SSC at room temperature before counterstaining with DAPI
(4′,6-diamindino-2-phenylindole). Using a BX61 fluorescent microscope (Olympus), the nu-
clei containing the RP11-62L18 (FGFR2) probe signals and the CEP 10 control signals were
examined within the areas marked, with 100 nuclei used to generate probe counts. Signal
patterns were documented using the Jai Progressive Scan camera and CytoVision
Imaging System (Leica Biosystems).
Immunohistochemist ry
Neuroendocrine (chromogranin and synaptophysin) and MMR IHC was performed accord-
ing to standard histological technique as previously described (Kushnir et al. 2014).
Briefly, 5-µm thick sections from the FFPE tissue block were labeled using a Benchmark
XT automated slide staining system (Ventana Medical Systems, Inc.) following standard pro-
tocols. Prediluted concentrations of the following monoclonal antibodies were used: anti-
Chromogranin A (Ventana Medical Systems, Inc.; clone LK2H10; monoclonal); anti-
Synaptophysin PMS2 (Cell Marque, Co.; clone MRQ-40; monoclonal); anti-MLH1 (Ventana
Medical Systems, Inc.; clone M1; monoclonal), anti-PMS2 (Cell Marque, Co.; clone
EPR3947; monoclonal), anti-MSH2 (Cell Marque, Co.; clone G219-1129; monoclonal), and
anti-MSH6 (Ventana Medical Systems, Inc.; clone 44; monoclonal). Ventana’s ultraView
Universal DAB Detection Kit was utilized and staining-visualized using hydrogen peroxide
substrate and a 3,3′-diaminodenzidine tetrahydrochloride (DAB) chromogen. Manufacture
recommendations were adhered to for antigen retrieval conditions (Ventana CC1, EDTA-
Tris, pH 8.0 solution). Nuclear staining for MLH1, PMS2, MSH2, and MSH6 was considered
positive. Lymphocytesand uninvolved colonic mucosa were used asan internal positive con-
trol for the MMRmarkers. Normal control colon was used as a positive control for the chro-
mogranin and synaptophysin IHC.
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